Phenotypic detection of ESBL and MBL in Gram Negative bacilli isolated from clinical specimens

Kamble D

1Miss. Deepali Shivajirao Kamble, Tutor, Department of Microbiology, SKNMC, Pune, India

Address for correspondence: Miss. Deepali Shivajirao Kamble, Email: deepali19kamble@yahoo.com

Abstract

Introduction: Antimicrobial resistance is a growing threat worldwide. The prevalence of Extended spectrum beta lactamases (ESBLs) and Metallobetalactamases (MBL) among Gram negative bacilli constitutes a serious threat to current beta-lactam therapy leading to treatment failure. Material and Methods: ESBL was detected by double disc diffusion test using ceftazidime alone and in combination with clavulanic acid. MBL detection was done by Imipenem EDTA combined disc diffusion test. Results: Out of 549 Gram negative bacilli resistant to 3G cephalosporin, 179(32.60%) were ESBL producers and out of 236 Gram negative bacilli resistant to carbapenem, 47(19.19%) were MBL producers. ESBL production was observed in E.coli, Klebsiella spp. Proteus spp and Citrobacter spp, while MBL production was observed in Pseudomonas aeruginosa, Acinetobacter spp, E.coli and Klebsiella spp isolated from various clinical samples. Conclusion: Simple disc method can be routinely employed to detect these common resistance mechanisms which will reduce the mortality and also spread of such resistant strains.

Keywords: Extended spectrum –beta lactamases, Metallobetalactamases, Gram Negative Bacilli.

Introduction

Resistant bacteria are emerging worldwide as a threat to the favorable outcome of common infections in community and hospital settings. Hospital acquired infections are most commonly caused by Gram-negative bacilli, particularly by members of Enterobacteriaceae family. These microbes are known to exhibit multidrug resistance. Beta-lactams (mainly extended-spectrum cephalosporins and carbapenems) and fluoroquinolones are used to treat infections caused by these microorganisms [1]. Resistance to third generation Cephalosporins is mediated by Extended Spectrum Beta Lactamase enzymes (ESBL) [2]. ESBLs are enzymes that mediate resistant to Cephalosporins and Aztreonam (but not the cephemcins or carbapenems) by hydrolysis and inhibited by by β-lactamase inhibitors such as clavulanic acid [3]. ESBL producing isolates, in addition to being resistant to β-lactam antibiotics, often exhibit resistance to other classes of drugs such as aminoglycosides, cotrimoxazole, tetracycline and Fluoroquinolones [4]. ESBLs are often located on plasmids that are transferable from strain to strain [5].

Carbapenems are used as drug of choice to treat infections caused by beta-lactam resistant bacteria. But extensive and sometime unnecessary use emergences carbapenem resistant bacteria. Resistance to carbapenem is predominantly mediated by metallo-

beta lactamases [6]. Early detection of MBL and ESBL producing organisms is crucial to establish appropriate antimicrobial therapy and to prevent their interhospital and intrahospital dissemination. So the present study was undertaken to detect ESBL and MBL in Gram negative bacilli from clinical isolates.

Material and Methods

The study was conducted in tertiary care hospital, Pune during 2009 to 2011. A total of 1278 Gram negative isolates were isolated from various samples (blood, urine, sputum, pus, fluids). They were processed and
identified by standard Microbiological procedures [7]. The antibiotics susceptibility testing was performed by Kirby-Bauer disc diffusion method using Clinical and Laboratory Standard Institute (CLSI) guidelines (2011). 549 isolates resistant to the third generation cephalosporins were tested for ESBL production and 236 isolates showing resistance to imipenem were tested for MBL production.

**Detection of ESBL:** This was performed by double disc diffusion method. Test organism were inoculated on Mueller hinton agar. The ceftazidime (30 µg) and ceftazidime-clavulanic acid (30 µg / 10 µg) were placed at a distance of 20 mm apart on the agar. An increase of ≥5mm in zone of inhibition of the combination discs in comparison to the ceftazidime disc alone was considered to be ESBL producer

**Detection of MBL:** This was performed by Imipenem EDTA combined disc test. Two (10 mcg) imipenem discs were placed on a plate inoculated with the test organism on Mueller hinton agar, and 10µl of 0.5 M EDTA solution was added to one disc. A zone diameter difference between the imipenem and imipenem + EDTA of ≥7 mm was interpreted as a positive result for MBL production.

**Results**

Out of 549 Gram negative bacilli 179 (32.60%) were ESBL producers and from 236 Gram negative bacilli 47(19.91%) were MBL producers. E. coli showed maximum ESBL production (35.23%).Maximum MBL producers was seen in Pseudomonas spp.(23.62%). Majority of ESBLs were isolated from urine followed by pus and sputum, while majority of MBL were from pus followed by urine.

| Organisms       | Total no. of isolates resistant to cephalosporin | Isolates positive by Ceftazidime and Ceftazidime-clavulanic acid double disc diffusion (%) |
|-----------------|-------------------------------------------------|-------------------------------------------------------------------------------------|
| E. coli         | 298                                             | 105 (35.23)                                                                          |
| Klebsiella spp. | 188                                             | 62 (32.97)                                                                           |
| Proteus spp.    | 54                                              | 11 (20.37)                                                                           |
| Citrobacter spp.| 5                                               | 1 (20)                                                                              |
| Salmonella spp. | 4                                               | 0 (00)                                                                              |
| **Total**       | **549**                                         | **179 (32.60)**                                                                     |

The majority of the ESBL producers were *E. coli* (35.23%) followed by *Klebsiella* spp. (32.97%). No ESBL producers were found among the *Salmonella* spp. and only one isolate (20%) of *Citrobacter* spp. was found to produce ESBLs

| Organisms               | Total no. of isolates resistant to carbapenem | Isolates positive by Imipenem EDTA double diffusion disc method (%) |
|-------------------------|-----------------------------------------------|-------------------------------------------------------------------|
| Pseudomonas aeruginosa  | 127                                           | 30 (23.62)                                                        |
| Acinetobacter spp.      | 80                                            | 15 (18.75)                                                        |
| E. coli                 | 18                                            | 01(5.55)                                                          |
| Klebsiella pneumoniae   | 11                                            | 01 (9.09)                                                         |
| **Total**               | **236**                                        | **47 (19.91%)**                                                   |

The majority of the MBL producers were *Pseudomonas aeruginosa* (23.62%) followed by *Acinetobacter* spp. (18.75%), *Klebsiella* spp. (9.09%) and *E. coli* (5.55%)
Table 3: Distribution of ESBL and MBL producers in various clinical specimens

| Specimens | ESBL producers (%) | MBL producers (%) |
|-----------|-------------------|-------------------|
| Blood     | 4(2.24)           | 3(6.38)           |
| Pus       | 71(39.66)         | 20(42.55)         |
| Urine     | 78(43.58)         | 19(40.42)         |
| Sputum    | 11(6.15)          | 0(0)              |
| Fluids    | 08(4.46)          | 2(4.2)            |
| CSF       | 0(0)              | 0(0)              |
| Others    | 07(3.92)          | 3(6.38)           |
| **Total** | **179(100)**      | **47(100)**       |

Maximum number of ESBLs producers were isolated from Urine 78 (43.58%) followed by pus 39.66%) While maximum number of MBLs producers were isolated from Pus 20 (42.55%) followed by urine (40.42%) No ESBLs and MBLs producers were reported from a cerebrospinal fluid (CSF).

Discussion

The emergence of antibiotic resistance is a matter of great concern, particularly in hospitals. Antibiotic resistant bacteria appear to be biologically fit and capable of causing serious life threatening infections. The increase in antibiotic resistance among gram-negative bacilli, such as Enterobacteriaceae group, *Pseudomonas aeruginosa* and others, is a notable example and how bacteria can maintain and express new genetic information that can confer resistance to one or several antibiotics. Resistance in gram-negative bacteria is a serious problem and calls for an effective infection control measures to curb their dissemination [8, 9].

Recent reports show that resistance to various groups of antibiotics particularly to fluoroquinolones and beta lactam antibiotics is increasing in the members of the family Enterobacteriaceae and *P. aeruginosa* making the treatment regimens limited.

In our study out of 549 Gram negative bacilli, 179 were ESBL producers. ESBLs were predominantly present among *E. coli* 105(35.23%) followed by *Klebsiella* spp. 62(32.97%), *Proteus* spp. 11(20.37%) and *Citrobacter* spp. 1( 20%).

Our findings of *E. coli* as the most common ESBLs producing Gram-negative bacilli followed by *Klebsiella* spp. is exactly similar to Agrawal et al, Tsering et al, Shiju et al. [10,11,12]. These studies also report *E. coli* as the most common ESBLs producing Gram-negative bacilli and *Klebsiella* spp. as the second most common ESBLs producing Gram-negative bacilli.

In our study out of 236 Gram negative bacilli, 47 were MBL producers. MBLs were predominantly present among *Pseudomonas spp* 30(23.62%) followed by *Acinetobacter* spp. 15(18.75%), *E.coli* 1(5.55%) and *Klebsiella* spp1(9.09%).

Our findings of *P. aeruginosa* as the most common MBLs producer correlate with Kumar et al.[16] Our findings of isolation of maximum number of MBLs producers from pus fairly correlates with Kumar et al. [17] & Rao et.al [18].

Correct identification of ESBL and MBL positive strains in due time is mandatory not only for optimal patient management but also for immediate institution of appropriate infection control measures to prevent the spread of these organisms. Simple disc method can be routinely employed to detect these resistant strains. Disc diffusion test would screen all ESBL and MBL Gram negative bacilli in the diagnostic laboratory. These methods are technically simple and inexpensive [19,20].

Conclusion
Simple phenotypic screening tests are proved to be rapid and convenient for the detection in the clinical laboratory. To overcome the problem of emergence and the spread of multidrug resistant organisms, a combined interaction and cooperation between the microbiologists, clinicians and the infection control team is needed.

Funding: Nil
Conflict of interest: None.
Permission of IRB: Yes

References

1. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008 Nov 20;13(47). pii: 19044.

2. Peshattiwar P D, Peerapur.B V. ESBL and MBL Mediated Resistance in Pseudomonas aeruginosa. J. Clin. Diagnostic Res.2011; 5(8): 1552-1554.

3. Sridhar Rao PN, Basavarajappa KG, Krishna GL. Detection of extended spectrum beta-lactamase from clinical isolates in Davangere. Indian J Pathol Microbiol. 2008 Oct-Dec;51(4):1552-1554.

4. Chandel DS, Johnson JA, Chaudhry R, Sharma N, Shinkre N, Parida S, Misra PR, Panigrahi P. Extended-spectrum beta-lactamase-producing Gram-negative bacteria causing neonatal sepsis in India in rural and urban settings. J Med Microbiol. 2011 Apr;60(Pt 4):500-7. doi: 10.1099/jmm.0.027375-0. Epub 2010 Dec 23.

5. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63(4):353-65.

6. Rajput A, Prajapati B, Chauhan B, Shah A, Trivedi T and Kadam M. Prevalence of Metallo-beta-lactamases (MBL) producing Pseudomonas aeruginosa in a tertiary care Hospital. Indian J. Basic.Appl. Med. Res. 2012; 1(4): 304-308.

7. Collee JG, Miles RS, Watt B. Tests for identification of bacteria. In: Collee JG, Fraser AG, Marmion BP and Simmons A editors. Mackie and McCartney Practical Medical Microbiology. 14th ed. Haryana: Churchill-Livingstone;2006. p.131-149.

8. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005 Apr;18(2):306-25.

9. Bradford PA. Extended-Spectrum -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin Microbiol Rev. 2001 Oct; 14(4): 933–951. doi: 10.1128/CMR.14.4.933-951.2001.

10. Agrawal P, Ghosh AN, Kumar S, Basu B, Kapila K. Prevalence of extended-spectrum beta-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital. Indian J Pathol Microbiol. 2008 Jan-Mar;51(1):139-42.

11. Tsering DC, Das S, Adhikari L, Pal R, Singh TS. Extended Spectrum Beta-lactamase Detection in Gram-negative Bacilli of Nosocomial Origin. J Glob Infect Dis. 2009 Jul;1(2):87-92. doi: 10.4103/0974-777X.56247.

12. Shiju MP, Yashavanth R, Narendra N. Detection of Extended Spectrum Beta-Lactamase Production and Multidrug Resistance in Clinical Isolates of E. coli and K. pneumoniae in Mangalore. J Clin Diagnos Res 2010;4:2442-2445.

13. Rao SP, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. Extended-Spectrum Beta-Lactamases Producing Escherichia coli and Klebsiella pneumoniae: A Multi-Centric Study Across Karnataka. J Lab Physicians. 2014 Jan;6(1):7-13. doi: 10.4103/0974-2727.129083.

14. Shashwati N, Kiran T, Dhanvijay AG. Study of extended spectrum β-lactamase producing Enterobacteriaceae and antibiotic coreistance in a tertiary care teaching hospital. J Nat Sci Biol Med. 2014 Jan;5(1):30-5. doi: 10.4103/0976-9668.127280.

15. Kusum M, Wongwanich S, Dhiraputra C, Pongpech P, Naenna P. Occurrence of extended-spectrum beta-lactamase in clinical isolates of Klebsiella pneumoniae in a University Hospital, Thailand. J Med Assoc Thai. 2004 Sep;87(9):1029-33.

16. Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol. 2006 Jul;24(3):208-11.
17. Kumar SH, Baveja SM, Gore MA. Prevalence and risk factors of Metallo β-lactamase producing Pseudomonas aeruginosa and Acinetobacter species in burns and surgical wards in a tertiary care hospital. J Lab Physicians. 2012 Jan;4(1):39-42. doi: 10.4103/0974-2727.98670.

18. Rao SD, Kumar EA. Antimicrobial resistance and metallo β lactamase in gram-negative isolates of hospital-acquired burn wound infections. J Dr NTR Univ Health Sci 2013;2:181-5.

19. Dalela G. Prevalence of Extended Spectrum Beta-Lactamase(ESBL) Producers among Gram Negative Bacilli from Various Clinical Isolates in a Tertiary Care Hospital at Jhalawar, Rajasthan, Indian. J. Clin. Diagnostic Res. 2012; 6(2): 182-187.

20. Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-beta-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2008 Jul-Sep;26(3):233-7.

How to cite this article?

Kamble D. Phenotypic detection of ESBL and MBL in Gram Negative bacilli isolated from clinical specimens. Int J Med Res Rev 2015;3(8):866-870. doi: 10.17511/ijmrr.2015.i8.163.